COMMUNIQUÉS West-GlobeNewswire

Transactions under Novonesis’ share buyback program
19/10/2026
Please read the announcement in PDF Attachment 2026_22_Share_buyback
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
19/10/2026
COPENHAGEN, Denmark, October 19, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount [...]
Prime Minister Mark Carney Sends Greetings as Canada Lights Up Sea-foam Green for International Stuttering Awareness Day
19/10/2026
From Niagara Falls to the CN Tower, landmarks across Canada will shine sea-foam green on October 22 as Canadians call for greater understanding and acceptance of stuttering. TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- [...]
Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
19/10/2026
Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 Congress Data supplements unprecedented two-year data from the trial including a 75% Objective Response [...]
RAMSAY GENERALE DE SANTE : Availability of the 2026 URD - Evolution in the Governance - Annual General meeting on 4th December 2026
19/10/2026
PRESS RELEASE Paris, 19 October 2026 EVOLUTION IN THE GOVERNANCE OF RAMSAY GENERALE DE SANTE AVAILABILITY OF THE 2026 UNIVERSAL REGISTRATION DOCUMENT ANNUAL GENERAL MEETING ON 4 DECEMBER 2026 Ramsay Health Care Limited [...]
RAMSAY GENERALE DE SANTE : Evolution de la gouvernance - Mise à disposition du DEU 2026 - Assemblée Générale du 4 décembre 2026
19/10/2026
COMMUNIQUÉ DE PRESSE Paris, le 19 octobre 2026 EVOLUTION DE LA GOUVERNANCE DE RAMSAY GENERALE DE SANTE MISE À DISPOSITION DU DOCUMENT D’ENREGISTREMENT UNIVERSEL 2026 ASSEMBLEE GENERALE DU 4 DECEMBRE 2026 Il est rappelé [...]
Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
19/10/2026
Markviss innritun sjúklinga með auknar líkur á meðferðarsvörun: 2/3 af þeim 176 sjúklingum sem innritaðir voru bera þann TNFR1-erfðabreytileika sem tengdur hefur verið aukinni klínískri svörun í fasa 2 rannsóknum. [...]
Nouscom Raises €120 Million ($135 Million) in Oversubscribed Series D Financing and will Present Long-Term Cancer Interception Clinical Data in Lynch Syndrome Carriers at ESMO
19/10/2026
Oversubscribed €120 million Series D financing was led by M Ventures and Revelation Partners, with new investors Angelini Industries, the European Investment Bank and Neva SGR and participation from all existing [...]
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
19/10/2026
High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials Precision Medicine Approach in a Large Market: [...]
Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telix
19/10/2026
The joint venture between IBA and Framatome will leverage Telix’s capabilities to accelerate the production and availability of Astatine-211 in the US market. Louvain-la-Neuve, Belgium, Paris, France, Indianapolis, [...]
Ekalia franchit une étape importante dans le déploiement de l’astate-211 aux États-Unis grâce à un accord de collaboration avec Telix
19/10/2026
La joint-venture entre IBA et Framatome s’appuiera sur les capacités de Telix afin d’accélérer la production et la disponibilité de l’astate-211 sur le marché américain. Louvain-la-Neuve, Belgique, Paris, France, [...]
OSE Immunotherapeutics Reports Positive Topline Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer
19/10/2026
Topline results to be presented by Federico Cappuzzo, MD, PhD, on October 25, 2026, at the Annual Meeting of the European Society for Medical Oncology (ESMO) in Madrid OSE Immunotherapeutics to host a KOL webcast on [...]
OSE Immunotherapeutics annonce les résultats de Topline positifs de l'étude de Phase 2 randomisée Combi-TED de Tedopi® (OSE2101) dans le cancer du poumon non à petites cellules métastatique
19/10/2026
Les résultats de Topline seront présentés par le Pr Federico Cappuzzo, PhD, le 25 octobre 2026 au congrès annuel de l’ European Society for Medical Oncology (ESMO) à Madrid OSE Immunotherapeutics organisera un webcast [...]
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
19/10/2026
Collaboration establishes a framework for a dedicated U.S. source of astatine-211 ( 211 At), a scarce, next-generation alpha-emitting isotope with significant potential in targeted alpha therapy (TAT). Secures long-term [...]
Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio
19/10/2026
Phase III Krascendo 1 results demonstrated divarasib’s superiority over current standard of care, first-generation KRAS G12C inhibitors in previously treated advanced G12C-mutated non-small cell lung cancer Patient- [...]
Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830
19/10/2026
Press release – No. 21 / 2026 Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830 ZP9830 is a novel Kv1.3 ion channel blocker [...]
JJP Biologics Doses the First Patients in Phase 1b Clinical Trial of Nebaprubart in Rheumatoid Arthritis (RA)
19/10/2026
Expansion of nebaprubart (JJP-1212) into RA follows positive interim data from its ongoing Phase 1b trial in linear IgA dermatosis (LAD), marking the second indication for the Company’s lead asset and expanding clinical [...]
IBA launches NEPTIS® Perform Duo, one synthesizer module from tracer development to routine production
19/10/2026
First new product from ORA, since IBA acquired ORA in December 2025 Louvain-la-Neuve, Belgium – October 19, 2026 7 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology [...]
IBA lance NEPTIS® Perform Duo, un module de synthèse unique pour le développement de traceurs et leur production de routine
19/10/2026
Premier nouveau produit lancé par ORA depuis son acquisition par IBA en décembre 2025. Louvain-la-Neuve, Belgique, 19 octobre 2026 à 7h00 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’ [...]

Pages